Treatment Outcomes of Patients With Different Subtypes of Large Cell Carcinoma of the Lung

Sun, Yung-Han; Lin, Shih-Wei; Hsieh, Chih‐Cheng; Yeh, Yi‐Chen; Tu, Cheng-Che; Chen, Kuan-Jeng

doi:10.1016/j.athoracsur.2014.05.012

Cited by 25 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognosis of the three LCC subtypes was compared by Sun et al, including 46 typical LCC, 30 large cell neuroendocrine carcinomas (LCNEC), and 18 LELC. LELC patients exhibited superior OS; the therapeutic outcome was also improved than the other two subtypes, and LELC was considered as an independent factor for prognosis (14). It was reported that the 2-year OS for different observations with 35, 52, and 74 LELC patients was 81%, 88%, and 86%, respectively, while the 5-year OS was 51%, 62%, and 72%, respectively (9,13,27).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma

et al. 2016

View full text Add to dashboard Cite

Background: Lymphoepithelioma-like carcinoma (LELC) is a rare form of non-small cell lung carcinoma.The current study focused on its clinicopathological features and potential factors influencing the prognosis.Methods: The statistical analysis was based on the clinicopathological records and the prognosis of 43 LELC patients, analyzed by Kaplan-Meier method, Log-rank test, and COX regression analysis.Results: The patients' average age was 57.35±9.22 years, 86.05% of them were non-smokers and 53.49%were women. The average tumor diameter was 3.24±1.57 cm. The 2-and 5-year overall survival (OS) rates of LELC patients were 90% and 74%, respectively; the disease-free survival (DFS) rates were 87% and 47%, respectively. The patients with large tumor, accompanied with lymph nodes metastasis or at the advanced stage had the worst OS, and the patients with lymph nodes metastasis or at the advanced stage had the worst DFS. Univariate analysis indicated that T and N grading and TNM stage influenced the OS, and N grading and TNM stage influenced the DFS; the independent factors affecting OS or DFS were not identified by multivariate analysis. Conclusions: LELC commonly occurred in senior non-smoking women. In summary, the prognosis of LELC was satisfactory.

show abstract

Section: Resultsmentioning

confidence: 99%

“…However, no independent Discussion LELC is a rare subtype of lung cancer. The patients were relatively young (13,14) and non-smokers (9,13-15). The incidence of LELC was not significantly different regarding gender (9).…”

Section: Resultsmentioning

confidence: 99%

Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Transl Lung Cancer Res 2016;5(6):720-726 tlcr.amegroups.com lung (10,19). Due to the rarity of LELC of the lung, there is a lack of prospective studies comparing various treatment strategies and therefore treatment guidelines are similar to those used for other forms lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature

Kim

Rajan

DeBrito

et al. 2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

“…The diverse heterogeneity observed between LCC and LCNEC in terms of cytological features and biological and clinical behavior to treatment have been reported. A study reported that LCNEC patients have significantly inferior overall survival (OS) after surgical resection compared to LCC patients, even in stage I disease . In addition, LCNEC exhibits differential cytological, clinical, and biological features than those of classic LCC, thus rendering controversy regarding its classification.…”

Section: Introductionmentioning

confidence: 99%

“…A study reported that LCNEC patients have significantly inferior overall survival (OS) after surgical resection compared to LCC patients, even in stage I disease. 6 In addition, LCNEC exhibits differential cytological, clinical, and biological features than those of classic LCC, thus rendering controversy regarding its classification. This classification system placed all lung cancers with large cell morphology in a group; however, it failed to address the biological behavior of these histological variants.…”

Section: Introductionmentioning

confidence: 99%

Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma

et al. 2019

View full text Add to dashboard Cite

Background The classification of large cell neuroendocrine carcinoma (LCNEC) has generated considerable debate and has been revised since its recognition as a separate entity. Although it shares clinical features with small cell lung carcinoma (SCLC) and was classified with SCLC in the 2015 World Health Organization classification system, numerous studies have revealed inferior treatment outcomes of LCNEC when it was treated as SCLC. Because the incidence of LCNEC is rare, its mutational landscape has not been comprehensively interrogated. Methods We performed capture‐based ultra‐deep targeted sequencing on tumor samples of LCNEC, large cell carcinoma (LCC), and SCLC to elucidate its biological relationship with these subtypes and to identify potentially targetable molecular alterations. Results Our data revealed a molecular signature, consisting of RUNX1 , ERBB4 , BRCA1 , and EPHA3 , that is distinctively mutated in LCNEC. A majority (60%) of LCNEC patients harbored copy number variations (CNVs). Interestingly, there were no common CNVs shared among the three subtypes: NFкBIA amplification was shared between LCNEC and LCC, while AKT2 amplification was shared between LCNEC and SCLC. Furthermore, genetic alterations in the PI3K/AKT/mTOR pathway were enriched in all three subtypes. Conclusion Despite the histological and/or morphological similarities among LCNEC, LCC, and SCLC, our data revealed a molecular signature, consisting of RUNX1 , ERBB4 , BRCA1 , and EPHA3 , that is distinctively mutated in LCNEC, which has the potential to be used as a panel of biomarkers to distinguish LCNEC from a molecular perspective. Furthermore, the molecular distinction among the three subtypes can also be reflected from CNV events.

show abstract

Treatment Outcomes of Patients With Different Subtypes of Large Cell Carcinoma of the Lung

Cited by 25 publications

References 26 publications

Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma

Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma

Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature

Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma

Contact Info

Product

Resources

About